Abeona Therapeutics® Reveals Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
CMS Establishes J-Code for ZEVASKYN: The Centers for Medicare and Medicaid Services (CMS) has created a permanent J-code for ZEVASKYN, an autologous gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), effective January 1, 2026.
Impact on Claims and Reimbursement: The new J-code will facilitate claims and reimbursement processes, enhancing hospital adoption and patient access to ZEVASKYN, according to Abeona Therapeutics' Chief Commercial Officer, Dr. Madhav Vasanthavada.
About ZEVASKYN: ZEVASKYN is the first cell sheet-based gene therapy for RDEB, addressing severe skin wounds by inserting the COL7A1 gene into patients' skin cells, leading to functional type VII collagen production.
Safety Information: ZEVASKYN may cause serious allergic reactions and has potential cancer risks; patients require lifelong monitoring for signs of cancer and should be aware of common side effects like pain and itching.
Trade with 70% Backtested Accuracy
Analyst Views on ABEO
About ABEO
About the author
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Nonprofit's Approach: A nonprofit organization is focusing on finding a cure for Epidermolysis Bullosa, a group of rare genetic skin disorders, by adopting a venture-capital-like strategy rather than traditional charity methods.
Goal Timeline: The organization aims to achieve its goal of finding a cure by the end of the decade.
Abeona Therapeutics Grants Equity Awards to New Employees
- Equity Award Program: On January 31, 2026, Abeona Therapeutics granted a total of 28,676 restricted shares to seven new employees as a material inducement for employment, aimed at enhancing the company's competitive edge in the biopharmaceutical sector.
- Vesting Conditions: The equity awards will vest one-third annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and motivation.
- Company Background: Abeona is a commercial-stage biopharmaceutical company focused on cell and gene therapies, with ZEVASKYN® being the first autologous cell-based gene therapy for treating serious diseases, showcasing its unique market value.
- Market Outlook: The company is developing adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs, which could further expand its market share through innovative product lines.
Analysis of High Insider Ownership Growth Companies in the U.S.
- High Insider Ownership: Super Micro Computer boasts 13.9% insider ownership while achieving 50.7% earnings growth, indicating strong performance and future growth potential in the tech sector.
- Profitability Improvement: Abeona Therapeutics recently became profitable with 10.3% insider ownership and is forecasted to grow revenue by 42.5% annually, enhancing its competitive position in gene and cell therapy.
- Market Expansion Potential: Streamex Corp. has 16.1% insider ownership and, despite a financial loss of $15.58 million, is projected to grow revenue by over 100% annually, showcasing its innovative capabilities in asset tokenization.
- Earnings Growth Expectations: Fiverr International, with 11.6% insider ownership, reported a net income of $5.54 million in Q3 2025, with projected earnings growth of 47.5% per year, reflecting strong momentum in the global online marketplace.
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees as a significant inducement for employment, aimed at attracting and retaining key talent to support the company's growth.
- Equity Structure: According to Nasdaq listing rules, the awarded shares will vest annually on the anniversary of the grant date, ensuring employee retention over three years, which enhances team stability and execution capability.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product, which is the first autologous cell-based gene therapy for treating severe skin diseases, showcasing the company's innovative potential in the biopharmaceutical sector.
- Market Outlook: Through this equity incentive, Abeona not only enhances employee loyalty but also potentially increases its attractiveness in the highly competitive biopharmaceutical market, aiding the company in achieving its long-term growth objectives.
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees, aimed at attracting and retaining talent, which is expected to enhance the company's competitive position in the biopharmaceutical sector.
- Vesting Arrangement: The restricted stock will vest annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and engagement.
- Compliance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), indicating that the company adheres to industry standards in its incentive mechanisms, which can bolster investor confidence.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product as an innovative solution for treating serious diseases, and the talent incentives are expected to further drive R&D advancements in the future.
Epidermolysis Bullosa Market Analysis 2025-2035: Innovations by Abeona, Castle Creek, RHEACELL, and Chiesi Drive Growth in Gene Therapies and Advanced Wound Care
Market Dynamics: The Epidermolysis Bullosa (EB) market is experiencing growth due to increased awareness of the disease, advancements in genetic research, and innovative treatments like gene therapies and advanced wound care products.
Key Players and Innovations: Companies such as Abeona Therapeutics and Castle Creek Biosciences are leading the market by developing new therapies and medical devices, focusing on regenerative medicine and personalized care to improve patient outcomes.
Challenges in Treatment: Despite promising advancements, challenges remain, including high treatment costs, limited diagnostic tools, and the rarity of EB, which complicates funding and research efforts.
Emerging Trends: The market is seeing a shift towards regenerative medicine and advanced wound care solutions, with a focus on stem cell therapies and specialized products designed to enhance healing and improve the quality of life for EB patients.
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Nonprofit's Approach: A nonprofit organization is focusing on finding a cure for Epidermolysis Bullosa, a group of rare genetic skin disorders, by adopting a venture-capital-like strategy rather than traditional charity methods.
Goal Timeline: The organization aims to achieve its goal of finding a cure by the end of the decade.
Abeona Therapeutics Grants Equity Awards to New Employees
- Equity Award Program: On January 31, 2026, Abeona Therapeutics granted a total of 28,676 restricted shares to seven new employees as a material inducement for employment, aimed at enhancing the company's competitive edge in the biopharmaceutical sector.
- Vesting Conditions: The equity awards will vest one-third annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and motivation.
- Company Background: Abeona is a commercial-stage biopharmaceutical company focused on cell and gene therapies, with ZEVASKYN® being the first autologous cell-based gene therapy for treating serious diseases, showcasing its unique market value.
- Market Outlook: The company is developing adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs, which could further expand its market share through innovative product lines.
Analysis of High Insider Ownership Growth Companies in the U.S.
- High Insider Ownership: Super Micro Computer boasts 13.9% insider ownership while achieving 50.7% earnings growth, indicating strong performance and future growth potential in the tech sector.
- Profitability Improvement: Abeona Therapeutics recently became profitable with 10.3% insider ownership and is forecasted to grow revenue by 42.5% annually, enhancing its competitive position in gene and cell therapy.
- Market Expansion Potential: Streamex Corp. has 16.1% insider ownership and, despite a financial loss of $15.58 million, is projected to grow revenue by over 100% annually, showcasing its innovative capabilities in asset tokenization.
- Earnings Growth Expectations: Fiverr International, with 11.6% insider ownership, reported a net income of $5.54 million in Q3 2025, with projected earnings growth of 47.5% per year, reflecting strong momentum in the global online marketplace.
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees as a significant inducement for employment, aimed at attracting and retaining key talent to support the company's growth.
- Equity Structure: According to Nasdaq listing rules, the awarded shares will vest annually on the anniversary of the grant date, ensuring employee retention over three years, which enhances team stability and execution capability.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product, which is the first autologous cell-based gene therapy for treating severe skin diseases, showcasing the company's innovative potential in the biopharmaceutical sector.
- Market Outlook: Through this equity incentive, Abeona not only enhances employee loyalty but also potentially increases its attractiveness in the highly competitive biopharmaceutical market, aiding the company in achieving its long-term growth objectives.
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees, aimed at attracting and retaining talent, which is expected to enhance the company's competitive position in the biopharmaceutical sector.
- Vesting Arrangement: The restricted stock will vest annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and engagement.
- Compliance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), indicating that the company adheres to industry standards in its incentive mechanisms, which can bolster investor confidence.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product as an innovative solution for treating serious diseases, and the talent incentives are expected to further drive R&D advancements in the future.
Epidermolysis Bullosa Market Analysis 2025-2035: Innovations by Abeona, Castle Creek, RHEACELL, and Chiesi Drive Growth in Gene Therapies and Advanced Wound Care
Market Dynamics: The Epidermolysis Bullosa (EB) market is experiencing growth due to increased awareness of the disease, advancements in genetic research, and innovative treatments like gene therapies and advanced wound care products.
Key Players and Innovations: Companies such as Abeona Therapeutics and Castle Creek Biosciences are leading the market by developing new therapies and medical devices, focusing on regenerative medicine and personalized care to improve patient outcomes.
Challenges in Treatment: Despite promising advancements, challenges remain, including high treatment costs, limited diagnostic tools, and the rarity of EB, which complicates funding and research efforts.
Emerging Trends: The market is seeing a shift towards regenerative medicine and advanced wound care solutions, with a focus on stem cell therapies and specialized products designed to enhance healing and improve the quality of life for EB patients.
